Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial

ABSTRACT A double-blind, randomised, parallel-group trial was conducted in patients with essential hypertension in British general practices, of nebivolol 5 mg, atenolol 50 mg, and placebo

each given once daily. Both active drugs, in comparison with placebo, caused highly significant and similar reductions in systolic and diastolic pressures without orthostatic effect, and

small significant falls in heart rate. Both active drugs were well tolerated, nebivolol marginally more so. Nebivolol, a long-acting, cardioselective, vasodilating beta-blocker which acts

partly via the l-arginine/nitric oxide mechanism, appears potentially valuable for the treatment of hypertension. Access through your institution Buy or subscribe This is a preview of

subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 digital issues and online access to articles $119.00 per

year only $9.92 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS EFFICACY AND

SAFETY OF ESAXERENONE (CS-3150) IN PRIMARY HYPERTENSION: A META-ANALYSIS Article Open access 04 January 2024 SUSTAINED-RELEASE ISOSORBIDE MONONITRATE AS ADJUVANT TREATMENT IN ISOLATED

SYSTOLIC HYPERTENSION IN THE ELDERLY Article 13 April 2021 EFFICACY OF SACUBITRIL/VALSARTAN VERSUS OLMESARTAN IN JAPANESE PATIENTS WITH ESSENTIAL HYPERTENSION: A RANDOMIZED, DOUBLE-BLIND,

MULTICENTER STUDY Article Open access 21 January 2022 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Janssen Research Foundation, Beerse, Belgium L Van Nueten & JIS Robertson * The

Surgery, Hexton Road, Barton le Clay, Bedfordshire, UK FR Taylor Authors * L Van Nueten View author publications You can also search for this author inPubMed Google Scholar * FR Taylor View

author publications You can also search for this author inPubMed Google Scholar * JIS Robertson View author publications You can also search for this author inPubMed Google Scholar RIGHTS

AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Van Nueten, L., Taylor, F. & Robertson, J. Nebivolol _vs_ atenolol and placebo in essential hypertension: a

double-blind randomised trial. _J Hum Hypertens_ 12, 135–140 (1998). https://doi.org/10.1038/sj.jhh.1000571 Download citation * Received: 20 June 1997 * Revised: 01 October 1997 * Accepted:

10 October 1997 * Published: 11 February 1998 * Issue Date: 01 February 1998 * DOI: https://doi.org/10.1038/sj.jhh.1000571 SHARE THIS ARTICLE Anyone you share the following link with will be

able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative KEYWORDS * nitric oxide * quality of life * side effects